acut
flaccid
myeliti
afm
rare
condit
associ
spinal
cord
gray
matter
abnorm
frequent
persist
motor
deficit
limb
present
experi
diagnosi
manag
outcom
affect
children
emphas
featur
trigger
earli
consider
afm
earli
viral
test
may
increas
rate
detect
associ
virus
j
pediatr
fm
defin
acut
onset
focal
limb
weak
correspond
spinal
cord
gray
matterspecif
abnorm
span
one
spinal
segment
magnet
reson
imag
mri
sometim
associ
brainstem
posterior
fossa
abnorm
afm
associ
varieti
virus
includ
enterovirus
eg
polioviru
enteroviru
ev
ev
weak
typic
begin
set
recent
current
respiratori
andor
febril
ill
may
rapidli
progress
despit
increas
case
us
diagnosi
often
delay
optim
treatment
regimen
defin
outcom
poorli
understood
use
case
seri
children
diagnos
afm
singl
tertiari
care
children
hospit
philadelphia
summar
clinic
infecti
imag
find
attent
detail
trigger
clinician
consid
diagnosi
afm
initi
clinic
present
also
summar
experi
treatment
regimen
report
outcom
data
children
perform
retrospect
chart
review
children
diagnos
afm
children
hospit
philadelphia
septemb
octob
studi
approv
children
hospit
philadelphia
institut
review
board
case
met
current
council
state
territori
epidemiologist
case
definit
afm
time
diagnosi
specif
case
acut
onset
focal
limb
weak
mri
demonstr
spinal
cord
lesion
larg
restrict
gray
matter
span
spinal
segment
case
confirm
us
center
diseas
control
prevent
cdc
probabl
case
exclud
abstract
demograph
epidemiolog
clinic
treatment
outcom
data
medic
record
confirm
case
use
modifi
rankin
scale
mr
ordin
scale
symptom
moder
disabl
requir
help
abl
walk
without
assist
moder
sever
disabl
unabl
walk
without
assist
attend
bodili
need
death
measur
disabl
respiratori
viru
multiplex
polymeras
chain
reaction
pcr
panel
test
respiratori
syncyti
viru
parainfluenza
viru
type
adenovirus
metapneumoviru
rhinovirus
rv
coronavirus
respiratori
specimen
perform
use
laboratori
develop
inhous
realtim
qualit
assay
respiratori
panel
often
unabl
differenti
rv
enterovirus
owe
genet
similar
posit
result
rv
report
rvev
posit
evspecif
monoplex
pcr
test
perform
use
roch
magnapur
system
roch
basel
switzerland
amplifi
quanstudio
dx
system
thermo
fisher
scientif
waltham
massachusett
ev
type
perform
avail
acut
sampl
children
suspect
afm
regardless
inhous
ev
test
result
cdc
atlanta
georgia
interv
ordin
variabl
describ
use
median
rang
intergroup
differ
compar
use
wilcoxon
ranksum
test
categor
variabl
describ
use
count
frequenc
intergroup
differ
compar
use
c
test
statist
signific
determin
priori
p
valu
fourteen
children
met
case
definit
confirm
case
afm
studi
time
period
n
n
children
diagnos
institut
consist
biennial
variat
incid
report
nation
demograph
clinic
characterist
diagnost
test
therapi
outcom
summar
tabl
children
weak
present
pronounc
proxim
five
children
promin
singl
limb
involv
upper
extrem
lower
extrem
multipl
limb
involv
thirteen
patient
underw
lumbar
punctur
demonstr
lymphocyt
predomin
pleocytosi
variabl
elev
protein
consist
afm
literatur
spinal
mri
children
demonstr
intraspin
gray
matter
hyperintens
consist
case
definit
commonli
midcerv
lower
thorac
region
figur
avail
wwwjped
com
twelv
children
underw
brain
mri
abnorm
found
brain
abnorm
includ
mening
enhanc
hyperintens
lesion
extend
spinal
cord
brainstem
basal
ganglia
figur
children
ev
test
perform
includ
screen
respiratori
viru
pcr
panel
andor
evspecif
pcr
test
nasopharyng
swab
tracheal
aspir
serum
cerebrospin
fluid
urin
andor
stool
ev
detect
tabl
ii
ten
children
screen
respiratori
viru
pcr
panel
rvev
posit
among
children
followup
evspecif
pcr
test
confirm
infect
child
neg
followup
evspecif
pcr
test
initi
care
outsid
institut
followup
test
delay
day
among
children
neg
respiratori
viru
pcr
panel
followup
evspecif
pcr
test
nasopharyng
swab
perform
posit
evspecif
pcr
test
one
site
conduct
patient
n
n
includ
children
screen
respiratori
viru
pcr
panel
ten
patient
posit
test
site
posit
test
common
compar
n
vs
n
posit
sampl
n
nasopharyng
swab
tracheal
aspir
cerebrospin
fluid
sampl
neg
tabl
patient
posit
nasopharyng
tracheal
aspir
also
posit
site
serum
stool
urin
stool
stool
one
patient
posit
ev
serum
stool
nasopharyng
aspir
sent
median
time
admiss
evspecif
pcr
test
day
rang
day
longer
compar
day
vs
day
ev
type
sampl
children
perform
cdc
one
children
posit
ev
followup
year
followup
evalu
mr
followup
evalu
volum
decemb
type
perform
sampl
children
children
posit
ev
nasopharyng
sampl
remain
children
delay
present
institut
acut
sampl
avail
type
children
sampl
procur
within
day
admiss
frequent
test
posit
ev
whose
sampl
drawn
later
n
vs
n
earlier
test
common
compar
vs
treatment
strategi
differ
institut
case
treat
idiopath
myeliti
intraven
methylprednisolon
n
andor
intraven
immunoglobulin
ivig
n
case
treat
intraven
methylprednisolon
n
ivig
n
fluoxetin
n
andor
plasma
exchang
n
children
demonstr
incomplet
recoveri
median
followup
year
rang
year
median
followup
mr
rang
score
repres
slight
improv
compar
median
mr
symptom
nadir
children
recov
fulli
one
children
present
isol
leg
weak
posit
ev
child
present
late
weak
set
febril
ill
posit
untyp
ev
respiratori
sampl
stool
urin
two
children
posit
ev
persist
flaccid
quadriplegia
requir
tracheostomi
gastrostomi
tube
followup
followup
mr
significantli
higher
among
children
test
posit
ev
compar
neg
test
median
n
vs
n
p
signific
differ
followup
mr
score
receiv
steroid
median
n
vs
n
p
children
receiv
ivig
fluoxetin
empir
ad
treatment
protocol
institut
administ
children
year
children
receiv
fluoxetin
higher
mr
score
followup
median
vs
children
receiv
plasma
exchang
median
vs
number
small
children
receiv
therapi
higher
nadir
mr
score
reflect
worsen
pretreat
function
compar
children
among
total
case
initi
receiv
altern
diagnosi
despit
weak
present
includ
viral
syndrom
neck
pain
n
guillainbarr
syndrom
n
viral
syndrom
brachial
nerv
palsi
n
toxic
synov
n
four
children
initi
discharg
emerg
room
upon
represent
worsen
symptom
requir
emerg
intub
ultim
requir
tracheostomi
afm
increasingli
recogn
caus
focal
flaccid
limb
weak
children
associ
signific
morbid
protocol
earli
diagnosi
prompt
sampl
acquisit
may
increas
yield
diagnost
test
despit
meet
clinic
criteria
afm
present
children
case
seri
delay
initi
diagnosi
although
afm
first
came
nation
attent
follow
case
seri
affect
children
colorado
report
similar
paralyt
ill
occur
past
pattern
asymmetr
proxim
greater
distal
weak
young
children
anteced
concurr
febril
ill
data
consist
prior
report
pain
also
common
complaint
diagnosi
case
seri
may
underestim
given
young
age
patient
increas
evid
associ
afm
ev
infect
whether
associ
relat
direct
viral
invas
spinal
cord
parainfecti
autoimmun
respons
infect
combin
two
remain
unclear
find
ev
pcr
test
cerebrospin
fluid
children
underw
lumbar
punctur
howev
find
evid
ev
infect
multipl
site
children
posit
evspecif
pcr
test
compar
new
institut
test
protocol
ensur
rapid
procur
standard
multisit
sampl
suspect
afm
case
unclear
whether
true
differ
sampl
bia
observ
underscor
import
rapid
sampl
acquisit
search
associ
pathogen
ev
type
previous
report
case
seri
reveal
strain
case
afm
anecdot
children
ev
neuroinvas
diseas
report
better
outcom
associ
ev
although
one
children
case
seri
posit
ev
child
good
outcom
compar
children
children
test
posit
ev
overal
poorer
outcom
test
neg
test
unclear
factor
may
confound
associ
also
possibl
anoth
unidentifi
viru
may
influenc
outcom
multipl
virus
includ
flavivirus
adenovirus
type
ev
also
associ
afm
phenotyp
antiinflammatori
treatment
immunemodul
therapi
result
improv
outcom
case
seri
nation
lack
treatment
effect
could
argu
autoimmun
neuropathogenesi
howev
data
may
confound
indic
sever
case
receiv
aggress
therapi
whether
outcom
improv
otherwis
would
without
therapi
unknown
concern
steroid
may
actual
detriment
afm
inde
caus
direct
viral
infect
spinal
cord
concern
base
histor
data
human
ev
outbreak
steroid
felt
worsen
clinic
cours
murin
model
ev
afm
found
mice
treat
highdos
steroid
increas
mortal
compar
untreat
mice
older
polioviru
data
demonstr
acceler
polioviru
replic
chick
embryo
treat
cortison
howev
definit
evid
advers
effect
never
clearli
shown
human
concern
well
perceiv
lack
efficaci
methylprednisolon
led
chang
intern
treatment
protocol
judici
use
steroid
primarili
restrict
concern
spinal
cord
edema
risk
secondari
injuri
treat
children
ivig
given
rel
low
risk
complic
potenti
modif
infect
mous
model
theoret
benefit
autoimmun
compon
pathophysiolog
afm
fluoxetin
treatment
implement
base
vitro
data
inhibit
replic
ev
clear
treatment
effect
retrospect
analysi
agent
sinc
remov
institut
treatment
protocol
highlight
observ
ad
new
therapi
lead
edg
knowledg
alway
success
ration
use
must
constantli
reassess
clinic
streamlin
treatment
protocol
afm
diagnosi
delay
almost
onehalf
children
case
seri
pain
may
mask
presenc
earli
subtl
weak
weak
afm
rapidli
progress
median
day
symptom
onset
nadir
symptom
proxim
weak
particular
easi
miss
screen
gener
medic
examin
presenc
recent
current
febril
ill
asymmetri
motor
function
even
initi
attribut
pain
prompt
thorough
neurolog
examin
consider
afm
studi
sever
limit
first
sampl
size
small
limit
singl
center
experi
analys
underpow
signific
associ
may
underestim
futur
studi
afm
requir
multisit
standard
protocol
increas
sampl
size
detect
subtl
associ
account
possibl
confound
use
multivari
regress
model
second
studi
retrospect
examin
motor
outcom
use
mr
could
appli
retrospect
howev
mr
insensit
measur
subtl
motor
chang
valid
pediatr
popul
develop
sensit
specif
outcom
measur
afm
critic
understand
fulli
natur
histori
ill
assess
efficaci
potenti
therapeut
option
third
patient
present
institut
variabl
time
acut
ill
abl
determin
reliabl
date
initi
symptom
onset
retrospect
analysi
therefor
time
etiolog
test
inconsist
may
introduc
falseneg
result
time
initi
treatment
also
variabl
optim
window
intervent
may
miss
final
steroid
plasma
exchang
larg
given
sicker
patient
therefor
confound
indic
may
obscur
potenti
treatment
effect
random
control
clinic
trial
would
address
limit
logist
difficult
rare
diseas
afm
sever
lifethreaten
underrecogn
caus
acut
onset
flaccid
limb
weak
pattern
rapidli
progress
asymmetr
proxim
distal
weak
context
current
recent
fever
absenc
sensori
find
trigger
consider
afm
prompt
recognit
improv
institut
develop
intern
protocol
suspect
case
afm
critic
appropri
clinic
monitor
ongo
epidemiolog
surveil
acquisit
sampl
laboratori
evalu
time
fashion
facilit
potenti
pathogen
identif
larger
futur
epidemiolog
studi
multisit
clinic
trial
may
lend
insight
neuropathogen
mechan
possibl
therapeut
strategi
n
